Optimizing antiretroviral product selection: A sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue SUPPL. 2, 2011, Pages

  Amole, Carolyn D ^a   Brisebois, Catherine ^a   Essajee, Shaffiq ^a   Koehler, Erin ^a   Levin, Andrew D ^a   Moore, Meredith C ^a   Brown Ripin, David H ^a   Sickler, Joanna J ^a   Singh, Inder R ^a,b  

^a CLINTON HEALTH ACCESS INITIATIVE   (United States)

^b NONE   (United States)

Author keywords

ARV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR;

ARTICLE; DEVELOPING COUNTRY; FUNDING; HEALTH CARE COST; HEALTH SERVICE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; HEALTH PLANNING; HEALTH SERVICES; HIV INFECTIONS; HUMANS; LAMIVUDINE; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; TREATMENT OUTCOME;

EID: 79959936415     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318220f016     Document Type: Article

References (14)

1. Aids 2031 Costs and Financing Working Group. Costs and Choices: Financing the Long-Term Fight Against AIDS. Washington, DC: Results for Development Institute; 2010.
2. World Health Organization (WHO). Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report .2010. Geneva, Switzerland: WHO; 2010.
3. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2010 Rev. Geneva, Switzerland; WHO; 2010.
4. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. NIH Web site. 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 9, 2011.
5. Médecins Sans Frontières. Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries. 8th ed. Geneva, Switzerland: Médecins Sans Frontières; 2006. Available at: http://utw.msfaccess.org/downloads. Accessed February 9, 2011.
6. Clinton Health Access Initiative. Antiretroviral (ARV) Price List. November .2010. William J. Clinton Foundation; 2010. Available at: http://www.clintonfoundation. org/what-we-do/clinton-health-access-initiative/ information-center-resources. Accessed February 9, 2011.
7. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53: 323-332.
8. DeJesus E, McCarty D, Farthing CF, et al. Once daily versus twice daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39:411-418. (Pubitemid 39050491)
9. Madruga JR, Cassetti I, Suleiman JM, et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials. 2007;8:381-390. (Pubitemid 350305212)
10. Benson CA, van der Horst C, LaMarca A, et al. Open label equivalence trial comparing 3TC 150 mg BID with FTC 200 mg QD. AIDS. 2004;18: 2269-2276.
11. Rey D, Hoen P, Chavanet P, et al. High rate of early virological failure with once-daily tenofovir/lamivudine/nevirapine combination in na?̈ve HIV-1-infected patients. J Antimicrob Chemother. 2009;63: 380-388.
12. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-na?̈ve HIV-infected patients. Clin Infect Dis. 2008; 46:1127-1129. (Pubitemid 351589888)
13. Sabin CA,Worm SW,Weber R, et al. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction (MI)? Recent use of abacavir and didanosine, but not of thymidine analogues, is associated with risk of myocardial infarction. Copenhagen HIV Program Web site. 2008. Available at: http://www.cphiv.dk/Portals/0/Files/Jens-CROI08-957c-300108. pdf. Accessed February 9, 2011.
14. Viread [package insert]. Foster City, CA: Gilead Science, Inc; 2010.